Table 4.
Survival analysis in POLE mutated EC
| Study | OS estimated HR (95% CI) | DSS estimated HR (95% CI) | PFS estimated HR (95% CI) | Survival analysis test | Method |
|---|---|---|---|---|---|
| Talhouk et al. (2017) [16] | 1.01 (0.29–3.42) | 0.42 (0.30–0.57) | - | Multivariable analysis | Kaplan-Meier survival analysis |
| Talhouk et al. (2015) [10] | 0.17 (0.01–1.98) | 0.170 (0.01–1.99) | - | Multivariable analysis | Kaplan-Meier with log-rank significance testing and Cox proportional hazard regression models |
| Church et al. (2015) [7] | 1.06 (0.58–1.91) | 0.19 (0.02–1.31) | - | Multivariable analysis | Kaplan-Meier method and compared by the log-rank test |
| Karnezis et al. (2017) [27] | 0.59 (0.21–1.60) | 0.49 (0.12–1.90) | 0.26 (0.04–1.49) | Univariable survival analysis | Kaplan-Meier survival curve |
| Stelloo et al. (2016) [20] | 1.10 (0.39–3.10) | Multivariable analysis | Kaplan-Meier survival analysis | ||
| Bosse et al. (2018) [13] | 0.23 (0.06–0.76) | Multivariable analysis | Kaplan-Meier survival curve | ||
| Pooled HR (95% CI) | 0.90 (0.59–1.38) | 0.41 (0.30–0.55) | 0.23 (0.08–0.64) | ||
| I2 (95% CI, %) | 0.00 (0.00–73.28) | 0.00 (0.00–67.34) | 0.00 (0.00–0.00) |
POLE, DNA polymerase epsilon; EC, endometrial carcinoma; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.